Priming with targeted activated t cells can enhance chemo responsiveness of cancer cells
AssigneeUniversity of Virginia Patent Foundation
InventorsLawrence G. Lum, Archana Thakur
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a targeted activated T cell, such as a bispecific antibody armed activated T cell (BAT), alone or in combination with an effective amount or a subtherapeutic amount of an additional therapeutic agent, wherein the targeted activated T cell selectively binds a cell of the cancer in the subject.
Claims34
A method for treating a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising a targeted activated T cell which selectively binds a cell of the cancer in the subject, to thereby treat the cancer in the subject.
A method for treating a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising a targeted activated T cell which selectively binds a cell of the cancer in the subject;
- and administering an effective amount or a subtherapeutic amount of an additional therapeutic agent to the subject, to thereby treat the cancer in the subject.
The method of any one of the preceding claims, wherein the targeted activated T cells are produced from an apheresis product.
The method of any one of the preceding claims, wherein the subject is a mammalian subject.
The method of any of the preceding claims, wherein the composition comprising the targeted activated T cell and/or the additional therapeutic agent is/are adapted for administration for the treatment of a subject by intravenous administration, intrathecal injection, peritoneal injection, or direct injection into the tumor or surrounding tumor site.
A pharmaceutical composition comprising, consisting essentially of, or consisting of an effective amount of a targeted activated T cell for use in treating a cancer in a subject in need thereof, wherein the targeted activated T cell selectively binds a cell of the cancer in the subject.
A pharmaceutical composition comprising, consisting essentially of, or consisting of an effective amount of a targeted activated T cell for use in a method for treating a cancer in a subject in need thereof, in combination with an effective amount or a subtherapeutic amount of an additional therapeutic agent, wherein the targeted activated T cell selectively binds a cell of the cancer in the subject.
The pharmaceutical composition of any one of claims 21-31, wherein the targeted activated T cells are produced from an apheresis product.
Dependencies are inferred from the claim text.